Eradication of liver-implanted tumors by semliki forest virus expressing IL-12 requires efficient long-term immune responses

Journal of Immunology

Volumn 190, Issue 6, 2013, Pages 2994-3004

  Quetglas, Jose I ^a   Juan, R Rodriguez Madoz ^a   Bezunartea, Jaione ^a   Marta, Ruiz Guillen ^a   Casales, Erkuden ^a   Jose, Medina Echeverz ^a   Prieto, Jesus ^a   Berraondo, Pedro ^a   Sandra, Hervas Stubbs ^a   Smerdou, Cristian ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15 RECEPTOR ALPHA; SFV IL 12; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; COLON ADENOCARCINOMA; COLON METASTASIS; FEMALE; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INTERFERON PRODUCTION; LIVER TUMOR; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; UPREGULATION;

ADENOCARCINOMA; ALPHAVIRUS INFECTIONS; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; COLORECTAL NEOPLASMS; CRICETINAE; FEMALE; GENETIC VECTORS; INTERLEUKIN-12; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SEMLIKI FOREST VIRUS;

EID: 84874868120     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201791     Document Type: Article

References (42)

1. Pawlik, T. M., and M. A. Choti. 2007. Surgical therapy for colorectal metastases to the liver. J. Gastrointest. Surg. 11: 1057-1077.
2. Wang, C. C., and J. Li. 2012. An update on chemotherapy of colorectal liver metastases. World J. Gastroenterol. 18: 25-33.
3. Nordlinger, B., E. Van Cutsem, T. Gruenberger, B. Glimelius, G. Poston, P. Rougier, A. Sobrero, and M. Ychou; European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop. 2009. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann. Oncol. 20: 985-992.
4. Weiss, J. M., J. J. Subleski, J. M. Wigginton, and R. H. Wiltrout. 2007. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin. Biol. Ther. 7: 1705-1721.
5. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
6. Voest, E. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87: 581-586.
7. Berraondo, P., J. Prieto, and G. Gonzalez-Aseguinolaza. 2009. Advances in interleukin-12 gene therapy for acquired liver diseases. Curr. Gene Ther. 9: 62- 71.
8. Barajas, M., G. Mazzolini, G. Genové, R. Bilbao, I. Narvaiza, V. Schmitz, B. Sangro, I. Melero, C. Qian, and J. Prieto. 2001. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 33: 52-61.
9. Quetglas, J. I., M. Ruiz-Guillen, A. Aranda, E. Casales, J. Bezunartea, and C. Smerdou. 2010. Alphavirus vectors for cancer therapy. Virus Res. 153: 179- 196.
10. Tahara, H., L. Zitvogel, W. J. Storkus, H. J. Zeh, III, T. G. McKinney, R. D. Schreiber, U. Gubler, P. D. Robbins, and M. T. Lotze. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154: 6466-6474.
11. Sangro, B., G. Mazzolini, J. Ruiz, M. Herraiz, J. Quiroga, I. Herrero, A. Benito, J. Larrache, J. Pueyo, J. C. Subtil, et al. 2004. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. 22: 1389-1397.
12. Penuelas, I., G. Mazzolini, J. F. Boán, B. Sangro, J. Martí-Climent, M. Ruiz, J. Ruiz, N. Satyamurthy, C. Qian, J. R. Barrio, et al. 2005. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128: 1787-1795.
13. Kung, A. L. 2007. Practices and pitfalls of mouse cancer models in drug discovery. Adv. Cancer Res. 96: 191-212.
14. Talmadge, J. E., R. K. Singh, I. J. Fidler, and A. Raz. 2007. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am. J. Pathol. 170: 793-804.
15. Strauss, J. H., and E. G. Strauss. 1994. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58: 491-562.
16. Liljeström, P., and H. Garoff. 1991. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N. Y.) 9: 1356-1361.
17. Rodriguez-Madoz, J. R., J. Prieto, and C. Smerdou. 2005. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol. Ther. 12: 153-163.
18. Ying, H., T. Z. Zaks, R. F. Wang, K. R. Irvine, U. S. Kammula, F. M. Marincola, W. W. Leitner, and N. P. Restifo. 1999. Cancer therapy using a self-replicating RNA vaccine. Nat. Med. 5: 823-827.
19. Zabala, M., P. Alzuguren, C. Benavides, J. Crettaz, G. Gonzalez-Aseguinolaza, C. Ortiz de Solorzano, M. Gonzalez-Aparicio, M. G. Kramer, J. Prieto, and R. Hernandez-Alcoceba. 2009. Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer progression in the liver and its response to immunogene therapy. Mol. Cancer 8: 2.
20. Quetglas, J. I., J. Fioravanti, N. Ardaiz, J. Medina-Echeverz, I. Baraibar, J. Prieto, C. Smerdou, and P. Berraondo. 2012. A Semliki forest virus vector engineered to express IFNa induces efficient elimination of established tumors. Gene Ther. 19: 271-278.
21. Smerdou, C., and P. Liljeström. 1999. Two-helper RNA system for production of recombinant Semliki forest virus particles. J. Virol. 73: 1092-1098.
22. Fleeton, M. N., B. J. Sheahan, E. A. Gould, G. J. Atkins, and P. Liljeström. 1999. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J. Gen. Virol. 80: 1189-1198.
23. Salminen, A., J. M. Wahlberg, M. Lobigs, P. Liljeström, and H. Garoff. 1992. Membrane fusion process of Semliki Forest virus. II: Cleavage-dependent reorganization of the spike protein complex controls virus entry. J. Cell Biol. 116: 349-357.
24. Garzón, M. R., P. Berraondo, J. Crettaz, L. Ochoa, M. Vera, J. J. Lasarte, A. Vales, N. Van Rooijen, J. Ruiz, J. Prieto, et al. 2005. Induction of gp120- specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. Vaccine 23: 1384-1392.
25. Chiodoni, C., P. Paglia, A. Stoppacciaro, M. Rodolfo, M. Parenza, and M. P. Colombo. 1999. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J. Exp. Med. 190: 125-133.
26. Obar, J. J., and L. Lefrançois. 2010. Memory CD8+ T cell differentiation. Ann. N. Y. Acad. Sci. 1183: 251-266.
27. Gabrilovich, D. I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12: 253-268.
28. Medina-Echeverz, J., J. Fioravanti, M. Zabala, N. Ardaiz, J. Prieto, and P. Berraondo. 2011. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J. Immunol. 186: 807-815.
29. Lodolce, J. P., P. R. Burkett, D. L. Boone, M. Chien, and A. Ma. 2001. T cellindependent interleukin 15Ralpha signals are required for bystander proliferation. J. Exp. Med. 194: 1187-1194.
30. Asselin-Paturel, C., N. Lassau, J. M. Guinebretière, J. Zhang, F. Gay, F. Bex, S. Hallez, J. Leclere, P. Peronneau, F. Mami-Chouaib, and S. Chouaib. 1999. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther. 6: 606-615.
31. Chikkanna-Gowda, C. P., B. J. Sheahan, M. N. Fleeton, and G. J. Atkins. 2005. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther. 12: 1253-1263.
32. Colmenero, P., M. Chen, E. Castanos-Velez, P. Liljeström, and M. Jondal. 2002. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int. J. Cancer 98: 554-560.
33. Quetglas, J. I., J. Dubrot, J. Bezunartea, M. F. Sanmamed, S. Hervas-Stubbs, C. Smerdou, and I. Melero. 2012. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol. Ther. 20: 1664-1675.
34. Riezebos-Brilman, A., J. Regts, M. Chen, J. Wilschut, and T. Daemen. 2009. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. Vaccine 27: 701-707.
35. Rodriguez-Madoz, J. R., K. H. Liu, J. I. Quetglas, M. Ruiz-Guillen, I. Otano, J. Crettaz, S. D. Butler, C. A. Bellezza, N. L. Dykes, B. C. Tennant, et al. 2009. Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma. J. Virol. 83: 12266-12278.
36. Pham-Nguyen, K. B., W. Yang, R. Saxena, S. N. Thung, S. L. Woo, and S. H. Chen. 1999. Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. Int. J. Cancer 81: 813-819.
37. Hansen, M. L., A. Woetmann, T. Krejsgaard, K. L. Kopp, R. Søkilde, T. Litman, P. T. Straten, C. Geisler, M. A. Wasik, N. Odum, and K.W. Eriksen. 2011. IFN-a primes T- and NK-cells for IL-15-mediated signaling and cytotoxicity. Mol. Immunol. 48: 2087-2093.
38. Hidmark, A. S., E. K. Nordström, P. Dosenovic, M. N. Forsell, P. Liljeström, and G. B. Karlsson Hedestam. 2006. Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling. J. Virol. 80: 7100-7110.
39. Burkett, P. R., R. Koka, M. Chien, S. Chai, F. Chan, A. Ma, and D. L. Boone. 2003. IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory. Proc. Natl. Acad. Sci. USA 100: 4724-4729.
40. Schluns, K. S., and L. Lefrançois. 2003. Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol. 3: 269-279.
41. Breitbach, C. J., J. Burke, D. Jonker, J. Stephenson, A. R. Haas, L. Q. Chow, J. Nieva, T. H. Hwang, A. Moon, R. Patt, et al. 2011. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102.
42. Hwang, T. H., A. Moon, J. Burke, A. Ribas, J. Stephenson, C. J. Breitbach, M. Daneshmand, N. De Silva, K. Parato, J. S. Diallo, et al. 2011. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol. Ther. 19: 1913-1922.